{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:06:35Z","timestamp":1794265595052,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006084","name":"Office of AIDS Research","doi-asserted-by":"publisher","award":["1B01NIAIDCU52002"],"award-info":[{"award-number":["1B01NIAIDCU52002"]}],"id":[{"id":"10.13039\/100006084","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Increased coagulation biomarkers are associated with poor outcomes among people living with HIV (PLHIV). There are few data available from African cohorts demonstrating the effect of antiretroviral therapy (ART) on coagulation biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From March 2014 to October 2014, ART-na\u00efve PLHIV initiating non-nucleoside reverse transcriptase inhibitor-based ART were recruited from seven clinics in western Kenya and followed for up to 12\u2009months. Demographics, clinical history and blood specimens were collected. Logistic regression models adjusted for intrasite clustering examined associations between HIV viral load and D-Dimer at baseline. Mixed linear effects models were used to estimate mean change from baseline to 6\u2009months overall, and by baseline viral load, sex and TB status at enrollment. Mean change in D-dimer at 6\u2009months is reported on the log10 scale and as percentage change from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 611 PLHIV enrolled, 66% were female, median age was 34\u2009years (interquartile range (IQR) 29\u201343\u2009years), 31 (5%) participants had tuberculosis and median viral load was 113,500 copies\/mL (IQR: 23,600-399,000). At baseline, 311 (50.9%) PLHIV had elevated D-dimer (\n                      <jats:underline>&gt;<\/jats:underline>\n                      \u2009500\u2009ng\/mL) and median D-dimer was 516.4\u2009ng\/mL (IQR: 302.7\u2013926.6) (log baseline D-dimer: 2.7, IQR: 2.5\u20133.0). Higher baseline D-dimer was significantly associated with higher viral load (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.0001), female sex (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.02) and tuberculosis (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u2009\u20090.02). After 6\u2009months on ART, 518 (84.8%) PLHIV had achieved viral load &lt;\u20091000 copies\/mL and median D-dimer was 390.0 (IQR: 236.6\u2013656.9) (log D-dimer: 2.6, IQR: 2.4\u20132.8). Mean change in log D-dimer from baseline to 6\u2009months was \u2212\u20090.12 (95%CI \u22120.15, \u2212\u20090.09) (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.0001) indicating at 31.3% decline (95%CI \u221240.0, \u2212\u200923.0) in D-dimer levels over the first 6\u2009months on ART. D-dimer decline after ART initiation was significantly greater among PLHIV with tuberculosis at treatment initiation (\u2212\u2009172.1, 95%CI \u2212259.0, \u2212\u2009106.3;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.0001) and those with log viral load &gt;\u20096.0 copies\/mL (\u2212\u200991.1, 95%CI \u2212136.7, \u2212\u200954.2;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large Kenyan cohort of PLHIV, women, those with tuberculosis and higher viral load had elevated baseline D-dimer. ART initiation and viral load suppression among ART-na\u00efve PLHIV in Kenya were associated with significant decrease in D-dimer at 6\u2009months in this large African cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05213-1","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:38:34Z","timestamp":1594719514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Changes in D-dimer after initiation of antiretroviral therapy in adults living with HIV in Kenya"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-8972","authenticated-orcid":false,"given":"Chloe A.","family":"Teasdale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Zerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Chege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hawken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa M.","family":"El-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"issue":"4","key":"5213_CR1","doi-asserted-by":"publisher","first-page":"ofx262","DOI":"10.1093\/ofid\/ofx262","volume":"4","author":"JV Baker","year":"2017","unstructured":"Baker JV, Sharma S, Grund B, et al. Systemic inflammation, coagulation, and clinical risk in the START trial. Open Forum Infect Dis. 2017;4(4):ofx262.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"5213_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/infdis\/jir134","volume":"203","author":"DR Boulware","year":"2011","unstructured":"Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203(11):1637\u201346.","journal-title":"J Infect Dis"},{"issue":"3","key":"5213_CR3","doi-asserted-by":"publisher","first-page":"e24243","DOI":"10.1371\/journal.pone.0024243","volume":"7","author":"L Ledwaba","year":"2012","unstructured":"Ledwaba L, Tavel JA, Khabo P, et al. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a south African cohort with advanced HIV disease. PLoS One. 2012;7(3):e24243.","journal-title":"PLoS One"},{"issue":"10","key":"5213_CR4","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","volume":"5","author":"LH Kuller","year":"2008","unstructured":"Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.","journal-title":"PLoS Med"},{"issue":"8","key":"5213_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","volume":"210","author":"AR Tenorio","year":"2014","unstructured":"Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248\u201359.","journal-title":"J Infect Dis"},{"issue":"3","key":"5213_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/infdis\/jiv450","volume":"213","author":"MJ Siedner","year":"2016","unstructured":"Siedner MJ, Kim JH, Nakku RS, et al. Persistent immune activation and carotid atherosclerosis in HIV-infected Ugandans receiving antiretroviral therapy. J Infect Dis. 2016;213(3):370\u20138.","journal-title":"J Infect Dis"},{"issue":"8","key":"5213_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/infdis\/jix113","volume":"215","author":"S Lee","year":"2017","unstructured":"Lee S, Byakwaga H, Boum Y, et al. Immunologic pathways that predict mortality in HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2017;215(8):1270\u20134.","journal-title":"J Infect Dis"},{"issue":"3","key":"5213_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00002030-200002180-00015","volume":"14","author":"PS Sullivan","year":"2000","unstructured":"Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The adult\/adolescent spectrum of HIV disease project. AIDS. 2000;14(3):321\u20134.","journal-title":"AIDS."},{"issue":"3","key":"5213_CR9","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S2352-3018(18)30333-3","volume":"6","author":"JFB Howard","year":"2019","unstructured":"Howard JFB, Rokx C, Smit C, et al. Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study. Lancet HIV. 2019;6(3):e173\u2013e81.","journal-title":"Lancet HIV"},{"issue":"5","key":"5213_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/01.qai.0000230320.78288.79","volume":"42","author":"AM Levine","year":"2006","unstructured":"Levine AM, Vigen C, Gravink J, et al. Progressive prothrombotic state in women with advancing HIV disease. J Acquir Immune Defic Syndr. 2006;42(5):572\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"5213_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/COH.0000000000000019","volume":"9","author":"NT Funderburg","year":"2014","unstructured":"Funderburg NT. Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS. 2014;9(1):80\u20136.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9170","key":"5213_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","volume":"353","author":"A Carr","year":"1999","unstructured":"Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093\u20139.","journal-title":"Lancet."},{"issue":"21","key":"5213_CR13","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa030218","volume":"349","author":"N Friis-Moller","year":"2003","unstructured":"Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993\u20132003.","journal-title":"N Engl J Med"},{"issue":"4","key":"5213_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","volume":"29","author":"NI Wada","year":"2015","unstructured":"Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29(4):463\u201371.","journal-title":"AIDS."},{"issue":"1","key":"5213_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/QAI.0b013e3181f7f61a","volume":"56","author":"JV Baker","year":"2011","unstructured":"Baker JV, Neuhaus J, Duprez D, et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr. 2011;56(1):36\u201343.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"5213_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/QAI.0000000000001629","volume":"77","author":"JR Castillo-Mancilla","year":"2018","unstructured":"Castillo-Mancilla JR, Morrow M, et al. Brief report: higher ART adherence is associated with lower systemic inflammation in treatment-naive Ugandans who achieve virologic suppression. J Acquir Immune Defic Syndr. 2018;77(5):507\u201313.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"5213_CR17","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/infdis\/jiv573","volume":"213","author":"R Shivakoti","year":"2016","unstructured":"Shivakoti R, Yang WT, Berendes S, et al. Persistently elevated C-reactive protein level in the first year of antiretroviral therapy, despite virologic suppression, is associated with HIV disease progression in resource-constrained settings. J Infect Dis. 2016;213(7):1074\u20138.","journal-title":"J Infect Dis"},{"key":"5213_CR18","unstructured":"Kenya National AIDS & STI Contorl Program. Guidlines on use of antiretroviral drugs for treating and prevening HIV infection: rapid advice. Nairobi: KEMRI; 2014."},{"issue":"1","key":"5213_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0038-1642375","volume":"71","author":"H Bounameaux","year":"1994","unstructured":"Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview. Thromb Haemost. 1994;71(1):1\u20136.","journal-title":"Thromb Haemost"},{"key":"5213_CR20","volume-title":"Global health observatory visualization: indicator metadata registry","author":"World Health Organization (WHO)","year":"2019","unstructured":"World Health Organization (WHO). Global health observatory visualization: indicator metadata registry. 2019. Available at: http:\/\/apps.who.int\/gho\/data\/node.wrapper.imr?x-id=1."},{"issue":"10","key":"5213_CR21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/hiv.12665","volume":"19","author":"EM Kiefer","year":"2018","unstructured":"Kiefer EM, Hoover DR, Shi Q, et al. Longitudinal evaluation of markers of inflammation in HIV-positive and HIV-negative Rwandan women. HIV Med. 2018;19(10):734\u201344.","journal-title":"HIV Med"},{"issue":"3","key":"5213_CR22","doi-asserted-by":"publisher","first-page":"e90978","DOI":"10.1371\/journal.pone.0090978","volume":"9","author":"AH Borges","year":"2014","unstructured":"Borges AH, O'Connor JL, Phillips AN, et al. Factors associated with D-dimer levels in HIV-infected individuals. PLoS One. 2014;9(3):e90978.","journal-title":"PLoS One"},{"issue":"8","key":"5213_CR23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/01.ATV.15.8.1094","volume":"15","author":"AJ Lee","year":"1995","unstructured":"Lee AJ, Fowkes GR, Lowe GD, Rumley A. Determinants of fibrin D-dimer in the Edinburgh artery study. Arterioscler Thromb Vasc Biol. 1995;15(8):1094\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"5213_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1553-2712.2010.00765.x","volume":"17","author":"C Kabrhel","year":"2010","unstructured":"Kabrhel C, Mark Courtney D, Camargo CA, et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med. 2010;17(6):589\u201397.","journal-title":"Acad Emerg Med"},{"issue":"7","key":"5213_CR25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/infdis\/jiz259","volume":"220","author":"MJ Siedner","year":"2019","unstructured":"Siedner MJ, Bwana MB, Asiimwe S, et al. Timing of antiretroviral therapy and systemic inflammation in sub-Saharan Africa: results from the META longitudinal cohort study. J Infect Dis. 2019;220(7):1172\u20137.","journal-title":"J Infect Dis"},{"issue":"4","key":"5213_CR26","first-page":"324","volume":"70","author":"LM Kager","year":"2015","unstructured":"Kager LM, Blok DC, Lede IO, et al. Pulmonary tuberculosis induces a systemic hypercoagulable state. J Inf Secur. 2015;70(4):324\u201334.","journal-title":"J Inf Secur"},{"issue":"1","key":"5213_CR27","first-page":"135","volume":"64","author":"W Min","year":"2018","unstructured":"Min W, Zi-Feng J, Jian-Lin X, Hao-Hui F. Role of the fibrinogen degradation products and D-dimer in the differential diagnosis of pulmonary tuberculosis and community-acquired pneumonia. Clin Lab. 2018;64(1):135\u201340.","journal-title":"Clin Lab"},{"key":"5213_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3851\/IMP3100","volume":"22","author":"S Janssen","year":"2017","unstructured":"Janssen S, Huson MAM, Osbak KK, et al. HIV infection rather than concurrent opportunistic infections drives most systemic procoagulant, vascular and damage responses \u2013 a prospective cohort study in central Africa. Antivir Ther. 2017;22:153\u201361.","journal-title":"Antivir Ther"},{"key":"5213_CR29","unstructured":"Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329368\/9789241565714-eng.pdf?ua=1. Accessed 1 Mar 2020."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05213-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05213-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05213-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T19:14:03Z","timestamp":1626203643000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05213-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5213"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05213-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-23729\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-23729\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-23729\/v3","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent to participate in the ARTIC study. The ARTIC study was approved by the Kenya Medical Research Institute (KEMRI) and the Columbia University Medical Center (CUMC) Institutional Review Board (IRB).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"508"}}